Cholangiocarcinoma is the second most common primary liver cancer. Its incidence is low in
the Western world but is rising globally. Surgery, chemotherapy and radiation therapy have …

Reversible, spatial, and temporal regulation of metabolic reprogramming and epigenetic
homeostasis are prominent hallmarks of carcinogenesis. Cancer cells reprogram their …

Isocitrate dehydrogenase 1 (IDH1) is the most commonly mutated metabolic gene across
human cancers. Mutant IDH1 (mIDH1) generates the oncometabolite (R)-2 …

IFN-γ, a soluble cytokine being produced by T lymphocytes, macrophages, mucosal
epithelial cells, or natural killer cells, is able to bind to the IFN-γ receptor (IFNγR) and in turn …

Intrahepatic cholangiocarcinoma (iCCA) exhibits extensive intratumoral heterogeneity and
an extremely high mortality rate. Here, we performed whole-exome sequencing, RNA …

Ten-eleven translocation (TET) family proteins (TETs), specifically, TET1, TET2 and TET3,
can modify DNA by oxidizing 5-methylcytosine (5mC) iteratively to yield 5 …

Cancer is a complex disease in which several molecular and cellular pathways converge to
foster the tumoral phenotype. Notably, in the latest iteration of the cancer hallmarks,“ …

The mutant IDH1 inhibitor ivosidenib improves outcomes for patients with IDH1-mutated
cholangiocarcinoma, but resistance inevitably develops. Mechanisms of resistance and …

Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary
tree. CCA has a poor prognosis, its clinical management remains challenging, and effective …

Biliary tract cancers are an uncommon set of gastrointestinal malignancies that are
associated with high morbidity and mortality rates. Most patients present with incurable …